Literature DB >> 21464061

Analytic reviews: propofol infusion syndrome in the ICU.

Daniel A Diedrich1, Daniel R Brown.   

Abstract

Propofol is an alkylphenol derivative named 2, 6, diisopropylphenol and is a potent intravenous short-acting hypnotic agent. It is commonly used as sedation, as well as an anesthetic agent in both pediatric and adult patient populations. There have been numerous case reports describing a constellation of findings including metabolic derangements and organ system failures known collectively as propofol infusion syndrome (PRIS). Although there is a high mortality associated with PRIS, the precise mechanism of action has yet to be determined. The best preventive measure for this syndrome is awareness and avoidance of clinical scenarios associated with development of PRIS. There is no established treatment for PRIS; care is primarily supportive in nature and may include the full array of advanced cardiopulmonary support, including extracorporeal membrane oxygenation (ECMO). This article reviews the reported cases of PRIS and describes the current understanding of the underlying pathophysiology and treatment options.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21464061     DOI: 10.1177/0885066610384195

Source DB:  PubMed          Journal:  J Intensive Care Med        ISSN: 0885-0666            Impact factor:   3.510


  24 in total

Review 1.  Drugs pharmacokinetics during veno-venous extracorporeal membrane oxygenation in pediatrics.

Authors:  Matteo Di Nardo; Enno Diederick Wildschut
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

2.  Propofol-related infusion syndrome heralding a mitochondrial disease: case report.

Authors:  Martin Savard; Nicolas Dupré; Alexis F Turgeon; Richard Desbiens; Stephan Langevin; Denis Brunet
Journal:  Neurology       Date:  2013-07-19       Impact factor: 9.910

Review 3.  Sedation for critically ill or injured adults in the intensive care unit: a shifting paradigm.

Authors:  Derek J Roberts; Babar Haroon; Richard I Hall
Journal:  Drugs       Date:  2012-10-01       Impact factor: 9.546

4.  Use of propofol for short duration procedures in children with long chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiencies.

Authors:  Julie M Martin; Melanie B Gillingham; Cary O Harding
Journal:  Mol Genet Metab       Date:  2014-04-06       Impact factor: 4.797

5.  Lipid metabolism disturbances and AMPK activation in prolonged propofol-sedated rabbits under mechanical ventilation.

Authors:  Wei Jiang; Zheng-bo Yang; Quan-hong Zhou; Xiang Huan; Li Wang
Journal:  Acta Pharmacol Sin       Date:  2011-12-12       Impact factor: 6.150

Review 6.  Drug-induced acid-base disorders.

Authors:  Daniel Kitterer; Matthias Schwab; M Dominik Alscher; Niko Braun; Joerg Latus
Journal:  Pediatr Nephrol       Date:  2014-11-05       Impact factor: 3.714

Review 7.  [Dexmedetomidine. Pharmacokinetics and pharmacodynamics].

Authors:  H Ihmsen; T I Saari
Journal:  Anaesthesist       Date:  2012-12       Impact factor: 1.041

Review 8.  Feline drug metabolism and disposition: pharmacokinetic evidence for species differences and molecular mechanisms.

Authors:  Michael H Court
Journal:  Vet Clin North Am Small Anim Pract       Date:  2013-09       Impact factor: 2.093

9.  Propofol infusion syndrome or not? A case report.

Authors:  James H Diaz; Cory A Roberts; Josh J Oliver; Alan David Kaye
Journal:  Ochsner J       Date:  2014

Review 10.  Mitochondrial Dysfunction in Critical Illness: Implications for Nutritional Therapy.

Authors:  Stephen A McClave; Paul E Wischmeyer; Keith R Miller; Arthur R H van Zanten
Journal:  Curr Nutr Rep       Date:  2019-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.